Friedrich Jung | Radiology | Best Researcher Award

Published on by Cognitive Scientist Awards

Prof. Dr. Friedrich Jung | Radiology | Best Researcher Award

Brandenburg Technical University | Germany

Professor Dr. Friedrich Jung is a distinguished biomedical scientist renowned for his pioneering contributions to molecular cell biology, biomaterials, and clinical hemorheology. He has built an illustrious career across leading German research institutions, serving in key academic and leadership roles, including as Director of the Institute for Heart and Circulation Research in Dresden and Head of the Department of Biointerface Engineering at the Berlin Brandenburg Center for Regenerative Therapies. With a strong academic foundation in physical and biomedical engineering from RWTH Aachen and Saarland University, he has significantly advanced the understanding of cell–material interactions and blood–biomaterial compatibility. His research interests encompass biomaterial development, molecular mechanisms of vascular responses, regenerative medicine, and translational biotechnologies aimed at improving clinical outcomes. Highly skilled in experimental cell biology, biointerface engineering, and quality management in biomedical systems, he has authored hundreds of peer-reviewed publications, book chapters, and scientific volumes. Professor Jung’s achievements have been recognised with prestigious honours such as the Robin Fahraeus, Otfried-Müller, and Oskar Orth Awards, and he has held leadership positions in European scientific societies. A visionary scholar and mentor, he continues to inspire innovation in biomedical science, bridging engineering and medicine for the advancement of human health and regenerative therapies.

Profile: Scopus

Featured Publications

Nuo Yu | Radiomics | Best Researcher Award

Published on by Cognitive Scientist Awards

Ms. Nuo Yu | Radiomics | Best Researcher Award

Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College ,China

Nuo Yu is a Ph.D. candidate at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, specializing in radiation oncology with a focus on esophageal squamous cell carcinoma (ESCC). His research primarily explores innovative chemoradiotherapy regimens to improve treatment outcomes for patients with locally advanced ESCC.

Yu has contributed to several peer-reviewed publications in SCI-indexed journals. Notably, he co-authored a study titled “Conversion Chemoradiotherapy Combined with Nab-Paclitaxel Plus Cisplatin in Patients with Locally Advanced Borderline-Resectable or Unresectable Esophageal Squamous Cell Carcinoma: A Phase I/II Prospective Cohort Study,” published in Strahlentherapie und Onkologie in August 2024. This research evaluated the efficacy and safety of a novel chemoradiotherapy regimen, demonstrating promising results in locoregional control and overall survival rates.

In March 2023, Yu co-authored another significant study, “Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study,” published in Current Cancer Drug Targets. This research focused on treatment strategies for elderly patients with ESCC, highlighting the potential benefits of combining chemoradiotherapy with nimotuzumab.

Yu’s work has been recognized at international conferences, including presentations at the American Society for Radiation Oncology (ASTRO), the Federation of Asian Organizations for Radiation Oncology (FARO), and the Korean Society for Radiation Oncology (KOSRO). These engagements underscore his active participation in the global radiation oncology community and his commitment to advancing cancer treatment research.

While still in the early stages of his career, Yu’s focused research on ESCC and his contributions to the field of radiation oncology position him as a promising candidate for the Best Researcher Award. Continued efforts to expand his research scope, increase publication impact, and assume leadership roles in larger-scale studies will further strengthen his candidacy.

Profile

Scientific Publications